IPHYF Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Innate Pharma SA

Watchlist Manager

Watchlist

Price: 1.65 USD Market Closed

Market Cap: $133.6m

I	Innate Pharma SA OTC:IPHYF	FR
J	Jungdawn Co Ltd KOSDAQ:208140	KR
I	Itoham Yonekyu Holdings Inc TSE:2296	JP
S	Shandong Keyuan Pharmaceutical Co Ltd SZSE:301281	CN
S	STRABAG SE DUS:XD4	AT
	AYRO Inc NASDAQ:AYRO	US
	Bharat Electronics Ltd BSE:500049	IN
P	Petroneft Resources PLC F:P8ET	IE

Profitability Summary

Innate Pharma SA's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Low Gross Margin

Strong 3Y Average Gross Margin

62%

Declining Gross Margin

93% > 1%

Negative Operating Margin

-1 834%

Negative 3Y Average Operating Margin

-653%

Declining Operating Margin

-152% > -1 834%

Negative Net Margin

-1 765%

Negative 3Y Average Net Margin

-615%

Declining Net Margin

-144% > -1 765%

Negative Free Cash Flow Margin

-1 898%

Negative 3Y Average Free Cash Flow Margin

-559%

Declining Free Cash Flow Margin

-74% > -1 898%

Exceptional ROE

764%

Exceptional 3Y Average ROE

Negative 3Y Average ROIC

-254%

Declining ROIC

-55% > -835%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.